3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Prostatic Neoplasms
142
Breast Neoplasms
97
Lung Neoplasms
72
Brain Neoplasms
67
Glioblastoma
59
Carcinoma, Non-Small-Cell Lung
54
Glioma
52
Pancreatic Neoplasms
39
Neoplasms
39
Neoplasm Metastasis
36
Colorectal Neoplasms
31
Carcinoma, Hepatocellular
30
Lymphoma, Large B-Cell, Diffuse
27
Carcinoma, Renal Cell
27
Multiple Myeloma
26
Squamous Cell Carcinoma of Head and Neck
25
Rectal Neoplasms
21
Melanoma
21
Ovarian Neoplasms
20
Astrocytoma
20
Urinary Bladder Neoplasms
18
Lymphoma, Follicular
18
Uterine Cervical Neoplasms
17
Colonic Neoplasms
17
Head and Neck Neoplasms
16
Lymphoma
15
Esophageal Neoplasms
15
Sarcoma
14
Lymphoma, Mantle-Cell
14
Lymphoma, B-Cell
14
Interventions
Carboplatin
6
Pemetrexed
3
Paclitaxel
3
atezolizumab
2
Radiosurgery
2
Gemcitabine
2
Docetaxel
2
Cisplatin
2
pembrolizumab
1
durvalumab
1
cemiplimab
1
Vinorelbine
1
Tyrosine Kinase Inhibitors
1
Radiotherapy
1
Platinum Compounds
1
Nivolumab
1
Mediastinoscopy
1
Magnetic Resonance Spectroscopy
1
Interleukin-15
1
Fluticasone
1
Exercise Therapy
1
Etoposide
1
Dasatinib
1
Bronchoscopy
1
Blood Specimen Collection
1
Bevacizumab
1
Afatinib
1
Acetylcysteine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Carcinoma, Bronchogenic
×
Magnetic Resonance Spectroscopy
×
Clear all
NCT00652769
2017-11-01
BOOST
University College London Hospitals
Phase 3
Completed
168 enrolled